Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)

Inclusion criteria

Line 1: - Age >18 at time of signing informed consent form

• Signed informed consent form Line 2: - Primery liver tumor
• Age >18 at time of signing informed consent form
• Signed informed consent form

Exclusion criteria

Line 1: - Active or history of neoplastic malignancy

• Active autoimmune disease ongoing treatment with immunosuppressive therapy
• Evidence of positive HIV, HCV, HBV test
• Diabetes
• Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months
• Chronic autoimmune or inflammatory diseases
• Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies
• Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for >3 years prior to signing informed consent and considered low risk of relapse
• HIV infection
• Failure to sign informed consent form